. Author manuscript; available in PMC: 2018 Sep 1.

Published in final edited form as: Cancer Immunol Res. 2017 Aug 17;5(9):767–777. doi: 10.1158/2326-6066.CIR-16-0365

Table 1.

Subsets of PD-L1^high cells in CMT167 and LLC tumors.

Cells (% of GFP+PD-L1^high by flow cytometry)	CMT167 orthotopic (n = 4 pools of 2 mice)	CMT167 subcutaneous (n = 7 tumors)	LLC orthotopic (n = 4 pools of 2 mice)
Alveolar macrophages	59.4 ± 4.98	N.D.	46.3 ± 4.40
Interstitial and monocyte-derived recruited macrophages	24.2 ± 2.03	67.66 ± 2.29	45.6 ± 4.33
Dendritic cells	4.0 ± 1.46	1.8 ± 1.60	1.5 ± 1.43
CD11b+Ly6G+ myeloid cells	N.D.	28.66 ± 1.60	2.5 ± 1.37
Endothelial cells	4.1 ± 1.44	1.8 ± 1.29	0.7 ± 0.66
Total PD-L1^high (% of GFP+ cells)	16.88 ± 0.84	8.05 ± 1.90	9.53 ± 0.95

Statistically significant differences by ANOVA compared to CMT167 orthotopic tumors are shown in bold. N.D. = not detected